Oritavancin
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Oritavancin: From Undocumented Original Indication to Bacteroidaceae Infectious Disease
One-Sentence Summary
Oritavancin is a lipoglycopeptide antibiotic; its original indication is not documented in this evidence pack, and it is not currently marketed in this jurisdiction. The TxGNN model predicts it may be effective for Bacteroidaceae infectious disease, but no clinical trials and no literature currently support this direction, and the drug's own mechanism of action argues against it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no license/indication data provided (drug not marketed) |
| Predicted New Indication | Bacteroidaceae infectious disease |
| TxGNN Prediction Score | 99.48% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Germany Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed MOA data is flagged as a data gap, but the evidence pack's own mechanistic rationale is informative: oritavancin is a lipoglycopeptide antibiotic that binds the D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting bacterial cell wall synthesis. This mechanism is only active against Gram-positive organisms.
Bacteroidaceae are Gram-negative anaerobes whose outer membrane blocks penetration of large glycopeptide molecules — mechanistically, oritavancin should not be active against this pathogen family. The rationale text explicitly labels this a likely TxGNN false positive, arising from the drug and disease being graph-adjacent "infectious disease" nodes rather than sharing a real pharmacological mechanism.
The other two candidates in this evidence pack (ophthalmic herpes zoster — a viral infection, and Mycoplasma pneumoniae pneumonia — a cell-wall-deficient bacterium) show the same pattern: high TxGNN scores paired with mechanistic incompatibility and zero clinical/literature support. This is not a case of a plausible signal awaiting evidence — the mechanism itself argues against the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Oritavancin is not marketed in this jurisdiction — no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Bacteroidaceae infectious disease) is mechanistically incompatible with oritavancin's Gram-positive-only spectrum, is unsupported by any clinical trial or literature evidence, and reflects TxGNN's L5 (prediction-only) tier. The two other candidates in this pack show the same pattern of mechanistic implausibility, suggesting a systematic false-positive cluster rather than a genuine repurposing signal.
To proceed, the following is needed:
- Confirmed MOA and original indication data from DrugBank/regulatory sources (currently marked as data gaps)
- TFDA/regulatory label warnings and contraindications (blocking gap — required before any S1 safety screening)
- Independent microbiological or in-vitro evidence of activity against Bacteroidaceae, if this candidate is to be pursued further
- Given the mechanistic red flags, recommend deprioritizing this candidate in favor of higher-evidence-level predictions elsewhere in the pipeline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.